Gefapixant citrate
Modify Date: 2024-01-03 03:18:07
Gefapixant citrate structure
|
Common Name | Gefapixant citrate | ||
|---|---|---|---|---|
| CAS Number | 2310299-91-1 | Molecular Weight | 545.52 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C20H27N5O11S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Gefapixant citrateGefapixant citrate is an orally active and potent purinergic P2X3 receptor (P2X3R) antagonist, with IC50 values of ~30 nM versus recombinant hP2X3 homotrimers and 100-250 nM at hP2X2/3 heterotrimeric receptors. Gefapixant citrate can be used for the research of chronic cough and knee osteoarthritis[1][2][3]. |
| Name | Gefapixant citrate |
|---|
| Description | Gefapixant citrate is an orally active and potent purinergic P2X3 receptor (P2X3R) antagonist, with IC50 values of ~30 nM versus recombinant hP2X3 homotrimers and 100-250 nM at hP2X2/3 heterotrimeric receptors. Gefapixant citrate can be used for the research of chronic cough and knee osteoarthritis[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
IC50: ~30 nM (recombinant hP2X3 homotrimers), 100-250 nM (hP2X2/3 heterotrimeric receptors)[1]. |
| In Vitro | Gefapixant citrate displays no inhibitory impact on any non-P2X3 subunit containing receptors (IC50 values >10,000 nM at recombinant homotrimeric hP2X1, hP2X2, hP2X4, rP2X5 and hP2X7 channels)[1]. |
| In Vivo | Gefapixant citrate (7d bid, orally) attenuates the weight bearing laterality with complete reversal of apparent hyperalgesia at the two higher doses in a rat model of knee osteoarthritis (14d following intra-articular administration of monoiodoacetate)[2]. |
| References |
| Molecular Formula | C20H27N5O11S |
|---|---|
| Molecular Weight | 545.52 |